PURPOSE: Inhaled nitric oxide (iNO), a pulmonary vasodilator, has demonstrated beneficial
effects in improving oxygenation among the ARDS population. However, the data regarding …

PURPOSE: COVID-19-related acute respiratory distress syndrome (ARDS) is associated
with profound hypoxia and changes in pulmonary hemodynamics. Inhaled nitric oxide (iNO) …

Abstract Introduction Nitric Oxide (NO) is an endogenous vasodilator that is synthesized by
the vascular endothelium. Due to its vasodilatory effect and short half-life, the use of NO as …

Rationale: Inhaled nitric oxide (iNO) has been used for several years as an adjunctive
therapy for improving oxygenation in adults with acute respiratory distress syndrome …

PURPOSE: Inhaled nitric oxide (iNO) is a potent vasodilator that has been studied as a
treatment for acute respiratory distress syndrome (ARDS). However, clinical trials have not …

RATIONALE: Severe COVID-19 may cause Acute Respiratory Distress Syndrome (ARDS), a
condition often characterised by major ventilation perfusion (V/Q) mismatch [1]. In patients …

Background Inhaled nitric oxide (iNO) has been widely used in patients with COVID-19-
related acute respiratory distress syndrome (C-ARDS), though its physiological effects and …

In adults with severe hypoxemia, inhaled nitric oxide (iNO) is known to reduce pulmonary
shunt and pulmonary hypertension, improving V/Q matching [1]. Studies in refractory …

Hypoxic patients with coronavirus disease 2019 (COVID-19) are at high risk of adverse
outcomes. Inhaled nitric oxide (iNO) has shown anti-viral and immunomodulatory effects in …

Background Inhaled nitric oxide (iNO) has been studied in patients with severe acute
respiratory distress syndrome (ARDS) due to COVID-19 when it may be too late to impact …